Metoprolol Succinate Tablet, Extended Release shortage
Metoprolol Succinate Tablet, Extended Release is currently listed in shortage by the FDA. The FDA lists 7 affected products. This page was last refreshed from FDA data on Sep 28, 2026.
Teva is permanently stopping its metoprolol succinate extended-release tablets — a heart and blood pressure medicine — across all strengths (25 mg, 50 mg, 100 mg, and 200 mg). Other manufacturers not reporting a shortage still list this same medicine in most strengths, so supply may be available from other sources.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Metoprolol Succinate Tablet, Extended Release. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Aug 31, 2026Currently in shortage7 of 7 products affected.
-
Aug 31, 2026First reported to the FDA7 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Teva Pharmaceuticals USA, Inc. 📞 800-545-8800 7 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-11) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-11) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Metoprolol Succinate, Tablet, Extended Release, 50 mg (NDC 45963-676-96) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-96) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Metoprolol Succinate, Tablet, Extended Release, 200 mg (NDC 45963-678-11) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Metoprolol Succinate, Tablet, Extended Release, 100 mg (NDC 45963-677-96) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
| To Be Discontinued | Metoprolol Succinate, Tablet, Extended Release, 25 mg (NDC 45963-709-11) | — | — | A business decision was made to discontinue manufacture of the drug. | — |
These rows are manufacturer reports to the FDA for Metoprolol Succinate Tablet, Extended Release — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Metoprolol Succinate Tablet, Extended Release? options further down this page.
Why is Metoprolol Succinate Tablet, Extended Release in shortage?
Teva Pharmaceuticals has made a business decision to permanently stop making their versions of metoprolol succinate extended-release tablets. This affects all four strengths they produced — the 25 mg, 50 mg, 100 mg, and 200 mg tablets — across their various package sizes. No specific reason beyond it being a business decision was shared publicly.
It's worth knowing that this report only covers Teva's products. Other manufacturers may still produce metoprolol succinate extended-release tablets and are listed separately. Teva simply chose, for their own business reasons, to exit this particular market entirely.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Metoprolol Succinate Tablet, Extended Release, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Metoprolol Succinate Tablet, Extended Release?
Metoprolol succinate extended-release tablets are currently on the FDA shortage list. I want to walk you through what this means so you can plan your next step calmly.
This shortage record comes from one manufacturer, Teva Pharmaceuticals, and it applies to all four strengths they made: 25 mg, 50 mg, 100 mg, and 200 mg — none of these have an available source from Teva right now. The reported reason is a business decision to discontinue making the drug. Because this is a discontinuation rather than a temporary delay, Teva's supply of this medicine is not expected to return. Importantly, this report only covers Teva; other companies still make the same medicine.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own — this medicine affects your heart and blood pressure.
- Ask your pharmacy to source metoprolol succinate ER from another maker. The same medicine and strengths are made by companies such as Major Pharmaceuticals, Cranbury Pharmaceuticals, Camber Pharmaceuticals, and Epic Pharma, though these may not be in local stock.
- If your exact strength can't be found, ask your prescriber or pharmacist about options, such as a different strength to make up your dose or another clinician-chosen choice.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Metoprolol Succinate Tablet, Extended Release?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Metoprolol Succinate Tablet, Extended Release is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Metoprolol Succinate | METOPROLOL SUCCINATE 25 mg/1 | Tablet, Film Coated, Extended Release · Oral | Major Pharmaceuticals | 00904-6322-06 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 50 mg/1 | Tablet, Film Coated, Extended Release · Oral | Major Pharmaceuticals | 00904-6323-61 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 100 mg/1 | Tablet, Film Coated, Extended Release · Oral | Major Pharmaceuticals | 00904-6324-61 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 25 mg/1 | Tablet, Extended Release · Oral | Cranbury Pharmaceuticals, LLC | 27808-0302-01 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 50 mg/1 | Tablet, Extended Release · Oral | Cranbury Pharmaceuticals, LLC | 27808-0303-01 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 100 mg/1 | Tablet, Extended Release · Oral | Cranbury Pharmaceuticals, LLC | 27808-0304-01 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 200 mg/1 | Tablet, Extended Release · Oral | Cranbury Pharmaceuticals, LLC | 27808-0305-01 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 25 mg/1 | Tablet, Film Coated, Extended Release · Oral | Camber Pharmaceuticals, Inc. | 31722-0589-01 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 50 mg/1 | Tablet, Film Coated, Extended Release · Oral | Camber Pharmaceuticals, Inc. | 31722-0590-01 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 100 mg/1 | Tablet, Film Coated, Extended Release · Oral | Camber Pharmaceuticals, Inc. | 31722-0591-01 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 200 mg/1 | Tablet, Film Coated, Extended Release · Oral | Camber Pharmaceuticals, Inc. | 31722-0592-01 |
| Metoprolol Succinate | METOPROLOL SUCCINATE 25 mg/1 | Tablet, Extended Release · Oral | Epic Pharma, LLC | 42806-0724-01 |
Alternative dosage forms of Metoprolol Succinate Tablet, Extended Release
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Metoprolol succinate 50 mg | Major | 1 tablet | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | Cranbury | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | Camber | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol succinate 50 mg | Epic | 100 tablets | $0.052 | AB | Availability likely |
| metoprolol succinate 50 mg | Actavis | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol succinate 50 mg | AvPAK | 1 tablet | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | Ingenus | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol succinate 50 mg | Dr. | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | American | 1 tablet | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | Ascend | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | BluePoint | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | BluePoint | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | BluePoint | 100 tablets | $0.052 | AB | Availability likely |
| metoprolol succinate 50 mg | Zydus | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | Granules | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol Succinate 50 mg | Oryza | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol succinate 50 mg | Northstar | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol succinate 50 mg | Dr. | 100 tablets | $0.052 | AB | Availability likely |
| Metoprolol succinate 50 mg | Quallent | 500 tablets | $0.052 | AB | Availability likely |
| metoprolol succinate 50 mg | Actavis | 1000 tablets | $0.052 | AB | Availability likely |
| Metoprolol succinate 50 mg | Slate | 100 tablets | $0.054 | AB | Availability likely |
| Metoprolol Succinate 50 mg | Nivagen | 1000 tablets | $0.059 | — | Discontinued |
| Metoprolol Succinate 100 mg | BluePoint | 100 tablets | $0.082 | AB | FDA listed |
| Metoprolol succinate 100 mg | Major | 1 tablet | $0.085 | AB | Availability likely |
| Metoprolol Succinate 100 mg | Cranbury | 100 tablets | $0.085 | AB | Availability likely |
| Metoprolol Succinate 100 mg | Camber | 100 tablets | $0.085 | AB | Availability likely |
| Metoprolol succinate 100 mg | Epic | 100 tablets | $0.085 | AB | Availability likely |
| metoprolol succinate 100 mg | Actavis | 100 tablets | $0.085 | AB | Availability likely |
| Metoprolol succinate 100 mg | AvPAK | 1 tablet | $0.085 | AB | Availability likely |
| Metoprolol Succinate 100 mg | Ingenus | 100 tablets | $0.085 | AB | Availability likely |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Metoprolol Succinate Tablet, Extended Release — that fall in the same broad treatment class (beta-adrenergic blocking agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other cardiovascular shortages
Metoprolol Succinate Tablet, Extended Release shortage FAQs
Is Metoprolol Succinate Tablet, Extended Release in shortage?
Which products are affected?
When will Metoprolol Succinate Tablet, Extended Release be available again?
Can I still get Metoprolol Succinate Tablet, Extended Release somewhere?
What should I do if I take Metoprolol Succinate Tablet, Extended Release?
Still have a question about the Metoprolol Succinate Tablet, Extended Release shortage?
Ask a pharmacist about this shortage →View Metoprolol Succinate Tablet, Extended Re... on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.